Biomarkers of cartilage turnover. Part 1: Markers of collagen degradation and synthesis

Veterinary Journal

Volumn 185, Issue 1, 2010, Pages 36-42

  Garvican, Elaine R ^a   Vaughan Thomas, Anne ^a   Innes, John F ^a   Clegg, Peter D ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Biomarkers; Collagen; Osteoarthritis

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; COLLAGEN ANTIBODY; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGENASE 3; EPITOPE; GELATINASE B; PROCOLLAGEN TYPE II C PROPEPTIDE; SCLEROPROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; CLINICAL FEATURE; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; DIAGNOSTIC ACCURACY; DISEASE COURSE; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME STRUCTURE; HUMAN; NONHUMAN; OSTEOARTHRITIS; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SYNOVIAL FLUID; TRIPLE HELIX; TURNOVER TIME; VETERINARY MEDICINE; ANIMAL; ARTICULAR CARTILAGE; BLOOD; DOG; DOG DISEASE; METABOLISM; PATHOLOGY; URINE; VETERINARY;

ANIMALS; BIOLOGICAL MARKERS; CARTILAGE, ARTICULAR; COLLAGEN TYPE II; DOG DISEASES; DOGS; OSTEOARTHRITIS; SYNOVIAL FLUID;

EID: 77953664216     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tvjl.2010.04.011     Document Type: Review

References (72)

1. 2 provide complementary information on type II collagen catabolism in healthy and osteoarthritic mice. Arthritis and Rheumatism 2007, 56:3336-3346.
2. Billinghurst R.C., Dahlberg L., Ionescu M., Reiner A., Bourne R., Rorabeck C., Mitchell P., Hambor J., Diekmann O., Tschesche H., Chen J., van Wart H., Poole A.R. Enhanced cleavage of type II collagen by collagenases in osteoarthritic cartilage. Journal of Clinical Investigation 1997, 99:1534-1545.
3. Billinghurst R.C., Wu W., Ionescu M. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase. Arthritis and Rheumatism 2000, 43:664-672.
4. Billinghurst R.C., Buxton E.M., Edwards M.G., McGraw M.S., McIlwraith C.W. Use of an anti-neoepitope antibody for identification of type-II collagen degradation in equine articular cartilage. American Journal of Veterinary Research 2001, 62:1031-1039.
5. Birmingham J.D., Vilim V., Kraus V.B. Collagen biomarkers for arthritis applications. Biomarker Insights 2007, 1:61-76.
6. Briot K., Roux C., Gossec L., Charni N., Kolta S., Dougados M. Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy. Journal of Rheumatology 2008, 35:310-314.
7. Caterson B., Flannery C.R., Hughes C., Little C.B. Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biology 2000, 19:333-344.
8. Charni N., Juillet F., Garnero P. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis and Rheumatism 2005, 52:1081-1090.
9. Christgau S., Garnero P., Fledelius C., Moniz C., Ensig M., Gineyts E. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001, 29:209-215.
10. Chu Q., Lopez M., Hayashi K., Ionescu M., Billingurst R.C., Johnson K.A., Poole A.R., Markel M.D. Elevation of a collagenase generated type II collagen neoepitope and a proteoglycan epitope in synovial fluid following induction of joint instability in the dog. Osteoarthritis and Cartilage 2002, 10:662-669.
11. Croucher L.J., Hollander A.P. Differential detection of type II collagen N-terminal and C-terminal denaturation epitopes in degrading cartilage. Molecular Pathology 1999, 52:323-331.
12. Davidson R., Waters J., Kevorkian L., Darrah C., Cooper A., Donell S., Clark I. Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage. Arthritis Research and Therapy 2006, 8:R124.
13. de Grauw J.C., van de Lest C.H., van Weeren R., Brommer H., Brama P.A. Arthrogenic lameness of the fetlock: synovial fluid markers of inflammation and cartilage turnover in relation to clinical joint pain. Equine Veterinary Journal 2006, 38:305-311.
14. de Grauw J.C., van de Lest C.H., van Weeren P.R. Inflammatory mediators and cartilage biomarkers in synovial fluid after a single inflammatory insult: a longitudinal experimental study. Arthritis Research and Therapy 2009, 11:R35.
15. 2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis and Cartilage 2005, 13:258-265.
16. Deberg M.A., Labasse A.H., Collette J., Seidel L., Reginster J.Y., Henrotin Y.E. One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis and Cartilage 2005, 13:1059-1065.
17. Evans C.H., Mears D.C., Stanitski C.L. Ferrographic analysis of wear in human joints. Evaluation by comparison with arthroscopic examination of symptomatic knees. Journal of Bone and Joint Surgery 1982, 64:572-578.
18. Eyre D.R., McDevitt C.A., Billingham M.E.J., Muir H. Biosynthesis of collagen and other matrix proteins by articular cartilage in experimental osteoarthrosis. Biochemical Journal 1980, 188:823-837.
19. Eyre D.R. Collagens and cartilage matrix homeostasis. Clinical Orthopaedics and Related Research 2004, 427:S118-S122.
20. Eyre D.R., Weis M.A. The helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence. Osteoarthritis and Cartilage 2009, 17:423-426.
21. Felson D.T., Lohmander L.S. Whither osteoarthritis biomarkers?. Osteoarthritis and Cartilage 2009, 17:419-422.
22. Fleming T.R., DeMets D.L. Surrogate end points in clinical trials: are we being misled?. Annals of Internal Medicine 1996, 125:605-613.
23. Frisbie D.D., Al-Sobayil F., Billinghurst R.C., Kawcak C.E., McIlwraith C.W. Changes in synovial fluid and serum biomarkers with exercise and early osteoarthritis in horses. Osteoarthritis and Cartilage 2008, 16:1196-1204.
24. Gangl M., Serteyn D., Lejeune J.P., Schneider N., Grulke S., Peters F., Vila T., Deby-Dupont G., Deberg M., Henrotin Y. A type II-collagen derived peptide and its nitrated form as new markers of inflammation and cartilage degradation in equine osteochondral lesions. Research in Veterinary Science 2007, 82:68-75.
25. Garnero P., Ayral X., Rousseau J.C., Christgau S., Sabdell L., Dougados M., Delmas P.D. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis and Rheumatism 2002, 46:21-30.
26. Garnero P., Charni N., Juillet F., Conrozier T., Vignon E. Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis. Annals of the Rheumatic Diseases 2006, 65:1639-1644.
27. Goranov N.V. Serum markers of lipid peroxidation, antioxidant enzymatic defense, and collagen degradation in an experimental (Pond-Nuki) canine model of osteoarthritis. Veterinary Clinical Pathology 2007, 36:192-195.
28. Garvican E.R., Anne Vaughan-Thomas A., Clegg P.F., Innes J.F. Biomarkers of cartilage turnover. Part 2: Non-collagenous markers. The Veterinary Journal 2010, 185:43-49.
29. Hayashi K., Kim S.Y., Lansdowne J.L., Kapatkin A., Déjardin L.M. Evaluation of a collagenase generated osteoarthritis biomarker in naturally occurring canine cruciate disease. Veterinary Surgery 2009, 38:117-121.
30. Henrotin Y., Deberg M., Dubuc J.E., Quettier E., Christgau S., Reginster J.Y. Type II collagen peptides for measuring cartilage degradation. Biorheology 2004, 41:543-547.
31. Hinek A., Reiner A., Poole A.R. The calcification of cartilage matrix in chondrocyte culture: studies of the C-propeptide of the type II collagen (chondrocalcin). Journal of Cell Biology 1987, 104:1435-1441.
32. Huebner J.L., Kraus V.B. Assessment of the utility of biomarkers of osteoarthritis in the guinea-pig. Osteoarthritis and Cartilage 2006, 14:923-930.
33. Hughes S.S., Hicks D.G., O'Keefe R.J., Hurwitz S.R., Crabb I.D., Krasinskas A.M. Shared phenotypic expression of osteoblasts and chondrocytes in fracture callus. Journal of Bone and Mineral Research 1995, 10:533-544.
34. Knauper V., Lopez-Otin C., Smith B., Knight G., Murphy G. Biochemical characterization of human collagenase-3. Journal of Biological Chemistry 1996, 271:1544-1550.
35. Kobayashi T., Yoshihara Y., Samura A., Yamada H., Shinmei M., Roos H. Synovial fluid concentrations of the C-propeptide of type II collagen correlate with body mass index in primary knee osteoarthritis. Annals of the Rheumatic Diseases 1997, 56:500-503.
36. Lejeune J.P., Serteyn D., Gangl M., Schneider N., Deby-Dupont G., Deberg M., Henrotin Y. Plasma concentrations of a type II collagen-derived peptide and its nitrated form in growing Ardenner sound horses and in horses suffering from juvenile digital degenerative osteoarthropathy. Veterinary Research Communications 2007, 31:591-601.
37. Lohmander L.S., Saxne T., Heinegard D.K. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Annals of Rheumatic Diseases 1994, 53:8-13.
38. Lohmander L.S., Yoshihara Y., Roos H., Kobayashi T., Yamada H., Shinmei M. Procollagen II C-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis. Journal of Rheumatology 1996, 23:1765-1769.
39. Lohmander L.S., Atley L.M., Pietka T.A., Eyre D.R. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis and Rheumatism 2003, 48:3130-3139.
40. Lu Y., Markel M.D., Swain C., Kaplan L.D. Development of partial thickness articular cartilage injury in an ovine model. Journal of Orthopaedic Research 2006, 24:1978-1982.
41. Matyas J.R., Ehlers P.F., Huang D., Adams M.E. The early molecular natural history of experimental osteoarthritis. I. Progressive discoordinate expression of aggrecan and type II procollagen messenger RNA in the articular cartilage of adult animals. Arthritis and Rheumatism 1999, 42:993-1002.
42. Matyas J.R., Atley L., Ionescu M., Eyre D., Poole A.R. Analysis of cartilage biomarkers in the early phases of canine osteoarthritis. Arthritis and Rheumatism 2003, 50:542-543.
43. Mazzuca S.A., Poole A.R., Brandt K.D., Katz B.P., Lane K.A., Lobanok T. Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis. Journal of Rheumatology 2006, 33:1147-1151.
44. Meyers S.L., Brandt K.D., Eilam O. Even low-grade synovitis significantly accelerates the clearance of protein from the canine knee. Implications for measurement of synovial fluid markers of osteoarthritis. Arthritis and Rheumatism 1995, 38:1085-1091.
45. Milner J., Rowan A., Cawston T., Young D. Metalloproteinase and inhibitor expression profiling of resorbing cartilage reveals pro-collagenase activation as a critical step for collagenolysis. Arthritis Research and Therapy 2006, 8:R142.
46. Mündermann A., Dyrby C.O., Andriacchi T.P., King K.B. Serum concentration of cartilage oligomeric matrix protein (COMP) is sensitive to physiological cyclic loading in healthy adults. Osteoarthritis and Cartilage 2005, 13:34-38.
47. Neidhart M., Müller-Ladner U., Frey W., Bosserhoff A.K., Colombani P.C., Frey-Rindova P., Hummel K.M., Gay R.E., Häuselmann H., Gay S. Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners. Osteoarthritis and Cartilage 2000, 8:222-229.
48. Nelson F., Dahlberg L., Laverty S., Reiner A., Pidoux I., Ionescu M., Fraser G.L., Brooks E., Tanzer M., Rosenberg L.C., Dieppe P., Poole R. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. Journal of Clinical Investigation 1998, 102:2115-2125.
49. Nemirovskiy O.V., Dufield D.R., Sunyer T., Aggarwal P., Welsch D.J., Mathews W.R. Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo. Analytical Biochemistry 2007, 361:93-101.
50. Nemirovskiy O.V., Sunyer T., Aggarwal P., Abrams M., Le Graverand M.P., Mathews W.R. Discovery and development of the N-terminal procollagen type II (NPII) biomarker: a tool for measuring collagen type II synthesis. Osteoarthritis and Cartilage 2008, 16:1494-1500.
51. Niyibizi C., Wu J.J., Eyre D. The carboxypeptide trimer of type II collagen is a prominent component of immature cartilages and intervertebral-disc tissue. Biochemica et Biophysica Acta 1987, 916:493-499.
52. Ohuchi E., Imai K., Fujii Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. Journal of Biological Chemistry 1997, 72:2446-2451.
53. Otterness I.G., Downs J.T., Lane C., Bliven M.L., Stukenbrok H., Scampoli D.N., Milici A.J., Mezes P.S. Detection of collagenase-induced damage of collagen by 9A4, a monoclonal C-terminal neoepitope antibody. Matrix Biology 1999, 18:331-341.
54. Petersson I.F., Boegard T., Svensson B., Heinegard D., Saxne T. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. British Journal of Rheumatology 1998, 37:46-50.
55. Poole A.R. Pathologic manifestations of joint disease in the athletic horse. Joint Disease in the Horse 1996, 87-104. WB Saunders Co., Philadelphia, PA, USA. C.W. McIllwraith, G.W. Trotter (Eds.).
56. Poole R. NIH White Paper: Biomarkers, the Osteoarthritis Initiative 2000, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, USA.
57. Poole A.R., Nelson F., Dahlberg L., Tchetina E., Kobayashi M., Yasuda T. Proteolysis of the collagen fibril in osteoarthritis. Biochemical Society Symposia 2003, 70:115-123.
58. Poole A.R., Ionescu M., Fitzcharles M.A., Billinghurst R.C. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. Journal of Immunological Methods 2004, 294:145-153.
59. Robion F.C., Doizé B., Bouré L., Marcoux M., Ionescu M., Reiner A., Poole A.R., Laverty S. Use of synovial fluid markers of cartilage synthesis and turnover to study effects of repeated intra-articular administration of methylprednisolone acetate on articular cartilage in vivo. Journal of Orthopaedic Research 2001, 19:250-258.
60. Roos H., Dahlberg L., Hoerrner L.A., Lark M.W., Thonar E.J., Shinmei M., Lindqvist U., Lohmander L.S. Markers of cartilage matrix metabolism in human joint fluid and serum: the effect of exercise. Osteoarthritis and Cartilage 1995, 3:7-14.
61. Rousseau J.C., Zhu Y., Miossec M.D., Vignon E., Sandell L.J., Garnero P., Dalmas P.D. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis and Cartilage 2004, 12:440-447.
62. Salminen H., Vuorio E., Saamanen A.M. Expression of sox9 and type II procollagen during attempted repair of articular cartilage damage in a transgenic mouse model of osteoarthritis. Arthritis and Rheumatism 2001, 44:947-955.
63. Sandell J. Alternatively spliced type II procollagen mRNAs define distinct populations of cells during vertebral development: differential expression of the amino-propeptide. Journal of Cell Biology 1991, 114:1307-1319.
64. Saxna T., Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. British Journal of Rheumatology 1992, 31:583-591.
65. Sharif M., Saxne T., Shepstone L. Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. British Journal of Rheumatology 1995, 34:306-310.
66. Sharif M., Kirwan J., Charni N., Sandell L.J., Whittles C., Garnero P. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis - association with disease progression. Rheumatology 2007, 46:938-943.
67. Shinmei M., Ito K., Matsuyama S., Yoshihara Y., Matsuzwaw K. Joint fluid carboxy-terminal type II procollagen peptide as a marker of cartilage collage biosynthesis. Osteoarthritis and Cartilage 1993, 1:121-128.
68. Spiers S., May S.A., Bennett D., Edwards G.B. Cellular sources of proteolytic enzymes in equine joints. Equine Veterinary Journal 1994, 26:43-47.
69. Todhunter R.J. Anatomy and physiology of synovial joints. Joint Disease in the Horse 1996, 1-28. WB Saunders Co., Philadelphia, PA, USA. C.W. McIllwraith, G.W. Trotter (Eds.).
70. Van den Steen P.E., Proost P., Grillet B., Brand D.D., Kang A.H., van Damme J. Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis. FASEB Journal 2002, 16:379-389.
71. Wilson C.G., Palmer A.W., Zuo F., Eugui E., Wilson S., Mackenzie R., Sandy J.D., Levenston M.E. Selective and non-selective metalloproteinase inhibitors reduce IL-1-induced cartilage degradation and loss of mechanical properties. Matrix Biology 2006, 26:259-268.
72. Zhu Y., Sandell L.J., Matyas J.R. Differential expression of type IIA collagen in early osteoarthritis. Transactions Orthopaedic Research Society 2001, 26:664-669.